1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL ANTI-ANEMIC DRUG MARKET ANALYSIS BY ANEMIA TYPE
5.1. Introduction
5.2. Iron Deficiency Anemia
5.3. Sickle Cell Anemia
5.4. Aplastic Anemia
5.5. Hemolytic Anemia
5.6. Pernicious Anemia
5.7. Others
6. GLOBAL ANTI-ANEMIC DRUG MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1. Introduction
6.2. Oral
6.3. Injection
7. GLOBAL ANTI-ANEMIC DRUG MARKET ANALYSIS BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom
7.4.4. Spain
7.4.5. Italy
7.4.6. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. Israel
7.5.3. UAE
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. South Korea
7.6.4. India
7.6.5. Indonesia
7.6.6. Thailand
7.6.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Amgen Inc.
9.2. GlaxoSmithKline plc.
9.3. Global Blood Therapeutics, Inc.
9.4. Akebia Therapeutics
9.5. Pieris Pharmaceuticals, Inc.
9.6. Acceleron Pharma
9.7. Johnson & Johnson
9.8. AdvaCare Pharma
9.9. Astellas Pharma Inc.
9.10. FibroGen, Inc.
LIST OF FIGURES
LIST OF TABLES